

IHC 2021

## **Real-world effectiveness data of erenumab-treated migraine patients in Switzerland: The SQUARE study**

**Elisabeth Schäfer<sup>1</sup>, Michael E. Arzt<sup>1</sup>, Ina Meyer<sup>1</sup>, Andreas R. Gantenbein<sup>2</sup>**

<sup>1</sup>Novartis Pharma Schweiz AG, Rotkreuz, Switzerland, <sup>2</sup>RehaClinic Bad Zurzach, Bad Zurzach, Switzerland

### **Objective:**

To present real-world effectiveness data of erenumab from the SQUARE (Swiss QQuality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population) study.

### **Methods:**

SQUARE is a non-interventional study which provides clinical effectiveness data on erenumab in a post-marketing setting from both migraine care specialist centers and general neurologists in Switzerland. Migraine patients receiving Aimovig® in accordance with the Swiss label were included if willing and able to participate, with the exception of patients with prior use of any medications targeting the calcitonin gene-related peptide (CGRP) pathway or recent use of investigational drugs. Patients were observed over a period of 24 months.

### **Results:**

A total of 173 adult patients were included in 19 centers. Here, we will present real-world effectiveness data of erenumab at month 6 compared to baseline, including scores of Headache Impact Test (HIT-6), modified (monthly) migraine disability assessment test (mMIDAS), and impact of migraine on partners and adolescent children (IMPAC).

### **Conclusion:**

These are among the first prospectively collected data on erenumab under routine medical care. Results from the SQUARE study will provide insights into the effectiveness of a CGRP receptor-based therapy in a real-world scenario.